TY - JOUR
T1 - Multi-center, pragmatic, cluster-randomized, controlled trial of standardized peritoneal dialysis (PD) training versus usual care on PD-related infections (the TEACH-PD trial)
T2 - trial protocol
AU - Chow, Josephine S.F.
AU - Boudville, Neil
AU - Cho, Yeoungjee
AU - Palmer, Suetonia
AU - Pascoe, Elaine M.
AU - Hawley, Carmel M.
AU - Reidlinger, Donna M.
AU - Hickey, Laura E.
AU - Stastny, Ruth
AU - Valks, Andrea
AU - Vergara, Liza
AU - Movva, Ramya
AU - Kiriwandeniya, Charani
AU - Candler, Hayley
AU - Mihala, Gabor
AU - Buisman, Bernadette
AU - Equinox, Keri Lu
AU - Figueiredo, Ana E.
AU - Fuge, Trudi
AU - Howard, Kirsten
AU - Howell, Martin
AU - Jaure, Allison
AU - Jose, Matthew D.
AU - Lee, Anna
AU - Miguel, Susana S.
AU - Moodie, Jo anne
AU - Nguyen, Thu T.
AU - Pinlac, Geraldine
AU - Reynolds, Annie
AU - Saweirs, Walaa W.M.
AU - Steiner-Lim, Genevieve Z.
AU - TeWhare, Bronwen
AU - Tomlins, Melinda
AU - Upjohn, Megan
AU - Voss, David
AU - Walker, Rachael C.
AU - Wilson, Joanne
AU - Johnson, David W.
N1 - Funding Information:
The TEACH-PD trial is funded by MRFF Clinical Trials Activity: Rare Cancers, Rare Diseases and Unmet Need Grant Opportunity (APP1170238); National Health & Medical Research Council (NHMRC) BEAT-CKD Program Grant (APP1092957); Health Research Council of New Zealand grant 19/290; Metro South Health Research Support Scheme Research Fund—Health System and Health Economics Project Grant; Queensland Health; South Western Sydney Research Small Grant Scheme; International Society for Peritoneal Dialysis; Translational Research Institute Australia; Amgen and Baxter Healthcare (see Additional file ).
Funding Information:
The authors acknowledge the contributions of the following individuals to The TEACH-PD Trial and this manuscript: Hussain Allawati (Te Whatu Ora Te Matua a Māui Hawkes Bay, Health New Zealand, New Zealand), Juan Arao (Royal Darwin Hospital, Tiwi, Northern Territory, Australia), Mark Arat (Royal Perth Hospital, Perth, Western Australia, Australia), Helen Ballantyne (Te Whatu Ora Coast and Hutt Valley, Health New Zealand, New Zealand), Shalimar Batucan (Mackay Hospital, Mackay, Queensland, Australia), Emily Beadle (Royal Hobart Hospital, Hobart, Tasmania, Australia), Julie Bloom (Royal Melbourne Hospital, Parkville, Victoria, Australia), Kathleen Branton (Royal Hobart Hospital, Hobart, Tasmania, Australia), Darren Browning (Royal Hobart Hospital, Hobart, Tasmania, Australia), Thanh Bui (Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia), Ernest Caballero (Te Whatu Ora Coast and Hutt Valley, Health New Zealand, New Zealand), Adele E Cave (Western Sydney University, Sydney, New South Wales, Australia), Tan Chiriso (Canberra Hospital, Canberra, Australian Capital Territory, Australia), Tracey Cloughly (Te Whatu Ora Waitaha Canterbury/Te Tai o Poutini West Coast, Health New Zealand, New Zealand), Camille Coladilla (Blacktown Hospital, Blacktown, New South Wales, Australia), Nicole Crawford (Sunshine Coast Hospital and Health Service, Birtinya, Queensland, Australia), Eric C Cueva (Te Whatu Ora Counties Manukau,Health New Zealand, New Zealand), Sue Curry (Te Whatu Ora Te Pae o Hauorao Ruahine o Tararua Mid Central/Whanganui, Health New Zealand, New Zealand), Matthew J Damasiewicz (Monash University, Clayton, Victoria, Australia), Daniel Davison (Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia), Laura Diaco (St. Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia), Alice Fernandis (Royal Adelaide Hospital, Adelaide, South Australia, Australia), Andrew Forbes (Monash University, Melbourne, Victoria, Australia), Cherie Forbes (Te Whatu Ora Waitaha Canterbury/Te Tai o Poutini West Coast, Health New Zealand, New Zealand), Sally Fox (Te Whatu Ora Counties Manukau,Health New Zealand, New Zealand), Alexander Gilbert (Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia), Megan Glover (Te Whatu Ora Counties Manukau,Health New Zealand, New Zealand), Kathleen Go (Te Whatu Ora Southern, Health New Zealand, New Zealand), Pamela Gordon (Sunshine Coast Hospital and Health Service, Birtinya, Queensland, Australia), Ankur Gupta (Te Whatu Ora Te Pae o Hauorao Ruahine o Tararua Mid Central/Whanganui, Health New Zealand, New Zealand), Jenny Heatley (Te Whatu Ora Te Tai Tokearu, Health New Zealand, New Zealand), Kerry Hodge (Royal Hobart Hospital, Hobart, Tasmania, Australia), Margaret Holcroft (Te Whatu Ora Waikato/Tairāwhiti, Health New Zealand, New Zealand), Amy Kang (Prince of Wales Hospital, Randwick, New South Wales, Australia), Peter G Kerr (Monash Medical Centre, Clayton, Victoria, Australia), Seon H Kim (Te Whatu Ora Counties Manukau,Health New Zealand, New Zealand), Linette Klattig-Johnson (Liverpool Hospital, Liverpool, New South Wales, Australia), Mel Laird (Orange Hospital, Orange, New South Wales, Australia), Holly Larsen (Nambour General Hospital-Sunshine Coast Hospital and Health Service, Birtinya, Queensland, Australia), Teena Lowe (Renal Research, Gosford, New South Wales, Australia), Win Lynd (Royal Hobart Hospital, Hobart, Tasmania, Australia), Abdul Majit (Te Whatu Ora Southern, Health New Zealand, New Zealand), Zainab A Modhefer (Western Sydney University, Sydney, New South Wales, Australia), Jane Moore (Te Whatu Ora Coast and Hutt Valley, Health New Zealand, New Zealand), Shane Morgan (Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia), Carmen Moroney (Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia), Vivienne Mourant (Royal Hobart Hospital, Hobart, Tasmania, Australia), Carolyn Murdoch (Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia), Rebecca Murton (Te Whatu Ora Coast and Hutt Valley, Health New Zealand, New Zealand), Bruce Neal (University of New South Wales, Kennington, New South Wales, Australia), Nicy Nelson (Te Whatu Ora Te Matua a Māui Hawkes Bay, Health New Zealand, New Zealand), Mary A Nicdao (Blacktown Hospital, Blacktown, New South Wales, Australia), Rea O'Brien-Puketapu (Te Whatu Ora Te Matua a Māui Hawkes Bay, Health New Zealand, New Zealand), Holly E Ratajec (Western Sydney University, Sydney, New South Wales, Australia), Fiona Robinson (St George Hospital, Kogarah, New South Wales, Australia), Maria D Rueda (St George Hospital, Kogarah, New South Wales, Australia), Soana Schaaf (Te Whatu Ora Counties Manukau,Health New Zealand, New Zealand), Tatiana Smolonogov (Blacktown Hospital, Blacktown, New South Wales, Australia), Bindu Sunny (Te Whatu Ora Te Matua a Māui Hawkes Bay, Health New Zealand, New Zealand), Fahimeh Taheri (Royal Hobart Hospital, Hobart, Tasmania, Australia), Maggie Thomas (Royal Brisbane And Women's Hospital, Herston, Queensland, Australia), Jennifer T Usher (Te Whatu Ora Waitaha Canterbury/Te Tai o Poutini West Coast, Health New Zealand, New Zealand), Emma Vella (St George Hospital, Kogarah, New South Wales, Australia), Christoph Wanner (Division of Nephrology, University Hospital Würzburg, Germany), Gerald Waters (Te Whatu Ora Waikato/Tairāwhiti, Health New Zealand, New Zealand), David C Wheeler (Department of Renal Medicine, University College London, London, United Kingdom), Jeffrey Wong (Liverpool Hospital, Liverpool, New South Wales, Australia), Abbey Wyard (Renal Research, Gosford, New South Wales, Australia). The authors acknowledge the following committees who have contributed to the trial’s development and operation: The TEACH-PD Global Steering Committee, The TEACH-PD Trial Management Committee, The TEACH-PD Trial Consumer Advisory Board, The TEACH-PD Trial Chief and Associate Investigators for the NHMRC, HRC and Metro South Health Research Support Scheme Research Fund—Health System and Health Economics Project Grants, Amgen, Baxter Healthcare, Queensland Health, The Home Network, Peritoneal Dialysis Working Group, Translational Research Institute, International Society for Peritoneal Dialysis, South Western Sydney Research—South Western Sydney Local Health District, Health Research Council New Zealand, New Zealand Peritoneal Dialysis Registry, The New Zealand PD Registry Steering Committee, The TEACH-PD Trial Data and Safety Monitoring Board, AKTN Executive Operations Secretariat, AKTN Leadership Team, AKTN Project Management Team, and AKTN Scientific Committee. The support of the following study sites has been integral to this trial, and they are acknowledged with thanks: Auckland Hospital, Austin Hospital, Barwon Health, Blacktown Mt Druitt Hospital & Nepean Hospital, Cairns Hospital, Canberra Hospital, Christchurch Hospital, Dunedin Hospital, Fiona Stanley Hospital, Gold Coast University Hospital, Gosford Hospital, Hawke's Bay Hospital, Launceston Hospital, Lismore Base Hospital, Liverpool Hospital, Logan Hospital, Mackay Base Hospital, Middlemore Hospital, Monash Medical, North Shore Hospital & Waitakere Hospital, Orange Health Service, Palmerston North Hospital (includes Wanganui Hospital), Prince of Wales Hospital, Princess Alexandra Hospital, Royal Adelaide Hospital, Royal Brisbane & Women's Hospital, Royal Darwin Hospital, Royal Hobart Hospital, Royal Melbourne Hospital, Royal North Shore Hospital, Royal Perth Hospital, Royal Prince Alfred Hospital & Concord Hospital, Sir Charles Gairdner Hospital, St George Hospital, St Vincent’s Hospital Melbourne, St Vincent's Health Sydney, Sunshine Coast University Hospital & Nambour Hospital , Tamworth Hospital, Taranaki Hospital, Toowoomba Hospital, The Tweed Hospital, Waikato Hospital (includes Gisborne Hospital), Wellington Hospital (Nelson Hospital and Blenheim Hospital), Whangarei Hospital. McCloud Consulting Group Pty Ltd provided statistical support to the trial. The trial investigators acknowledge the provision of the EQ-5D-5L questionnaire used in the study by The EuroQol Research Foundation, Rotterdam, The Netherlands. The trial investigators acknowledge the provision of the PROMIS questionnaire used in the study by PROMIS Health Organization and PROMIS Cooperative Group, River Forest, Illinois. Study data were collected and managed using REDCap electronic data capture tools hosted at The University of Queensland [33 , 35 ]. REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing (1) an intuitive interface for validated data capture; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for data integration and interoperability with external sources. Collaborators Marilyn Aday (Te Whatu Ora Te Pae o Hauorao Ruahine o Tararua Mid Central/Whanganui, Health New Zealand, New Zealand), Kathryn Anderson (Orange Hospital, Orange, New South Wales, Australia), Laraine Aw (Blacktown Hospital, Blacktown, New South Wales, Australia), Monica Bexton (St Vincent's Hospital, Sydney, New South Wales, Australia), Mary Bodilsen (Canberra Hospital, Canberra, Australian Capital Territory, Australia), Caroline Chembo (Te Whatu Ora Coast and Hutt Valley, Health New Zealand, New Zealand), Michael G Collins (Royal Adelaide Hospital, Adelaide, South Australia, Australia), Anna C Cuesta (St George Hospital, Kogarah, New South Wales, Australia), Blair Donkin (Te Whatu Ora Southern, Health New Zealand, New Zealand), Kathryn Eggleton (Te Whatu Ora Waikato/Tairāwhiti, Health New Zealand, New Zealand), Stephanie Fisk (Logan Hospital, Meadowbrook, Queensland, Australia), Jenny Franco (Te Whatu Ora Te Matua a Māui Hawkes Bay, Health New Zealand, New Zealand), Puniloa Fuka (Te Whatu Ora Counties Manukau, Health New Zealand, New Zealand), Natalie Grainer (Cairns Hospital, Cairns, Queensland, Australia), Alok Gupta (Toowomba Hospital, Toowomba, Queensland, Australia), Ashik Hayat (Princess Alexandra Hospital, Brisbane, Queensland, Australia), Penny Hill (Te Whatu Ora Waitaha Canterbury/Te Tai o Poutini West Coast, Health New Zealand, New Zealand), Peggy P H Hoo (Te Whatu Ora Te Toka Tumai, Health New Zealand, New Zealand), Jamie Kendrik-Jones (Te Whatu Ora Counties Manukau, Health New Zealand, New Zealand), Christine King (Royal North Shore Hospital, ST.LEONARDS, New South Wales, Australia), Rathika Krishnasamy (Sunshine Coast University Hospital, Sunshine Coast, Queensland, Australia), Lin Lin (Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia), Moira A Maley (The University of Western Australia, Western Australia, Australia), Bernadette McAlister (Te Whatu Ora Coast and Hutt Valley, Health New Zealand, New Zealand), Kim McNamara (Tamworth Hospital, Tamworth, New South Wales, Australia), Melisa Mlambo (Princess Alexandra Hospital, Brisbane, Queensland, Australia), Michelle Ovenden (Royal Adelaide Hospital, Adelaide, South Australia, Australia), Morgan Park (Te Whatu Ora Te Pae o Hauorao Ruahine o Tararua Mid Central/Whanganui, Health New Zealand, New Zealand), Khalil Patankar (Royal Perth Hospital, Perth, Western Australia, Australia), Peta-Anne Paul-Brent (Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland, Brisbane, Queensland, Australia), Bidhun K Paulose (Royal Darwin Hospital, Tiwi, Northern Territory, Australia), Kylie Pegg (Griffith University, Brisbane, Queensland, Australia), Andrea Pollock (Sunshine Coast Hospital and Health Service, Birtinya, Queensland, Australia), Glenda Rayment (Liverpool Hospital, Liverpool, New South Wales, Australia), Isabelle Renaudin (St. Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia), Matthew A Roberts (Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia), Robyn Rogers (Logan Hospital, Meadowbrook, Queensland, Australia), Sivatha Ros (Austin Health, Melbourne, Victoria, Australia), Jane Ruane (Lismore Hospital, Lismore, New South Wales, Australia), Lisa Shelverton (Royal Hobart Hospital, Hobart, Tasmania, Australia), Rosemary Simmonds (Barwon Health, Corio, Victoria, Australia), Christine Somerville (Barwon Health, Corio, Victoria, Australia), Kamal Sud (Nepean Kidney Research Centre, Department of Renal Medicine, Nepean Hospital, Sydney, New South Wales, Australia), Nadine Tinsley (Royal Darwin Hospital, Tiwi, Northern Territory, Australia), David Troy (Tweed Hospital, Tweed Heads, New South Wales, Australia), Andrea K Viecelli (Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland, Brisbane, Queensland, Australia), Rob Walker (University of Otago, Christchurch, Christchurch, New Zealand), Paula Woodward (The Med Collective (Medical Education and Communications), Sydney, New South Wales, Australia), Kerry Yaxley (Te Whatu Ora Waitaha Canterbury/Te Tai o Poutini West Coast, Health New Zealand, New Zealand), Hee-eun ‘Ellen’ Yeo (Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia).
Funding Information:
Josephine S F Chow has previously received speaker’s honoraria and research funds from Baxter Healthcare, Fresenius Medical Care, Roche Pharmaceuticals and Amgen. Neil Boudville has Otsuka honorarium. Advisory board member for Astra Zeneca Advisory Board, GSK Advisory Board and Vifor Advisory Board. Received consultancy fees from Baxter Healthcare. Yeoungjee Cho has Speaker’s honoraria and research grants from Baxter Healthcare and Fresenius Medical Care. Walaa W M Saweirs has Speaker’s honoraria from Baxter. Rachael C Walker has previously received speaker’s honoraria and research funds from Baxter Healthcare. David W Johnson has previously received consultancy fees, research grants, speaker’s honoraria, and travel sponsorships from Baxter Healthcare and Fresenius Healthcare. Megan Upjohn attended Baxter Education Days in last few years. Rathika Krishnasamy received grants and speaking honoraria from Baxter International. Received consultancy fees from Astra Zeneca. Kamal Sud has speaker’s honoraria from Baxter Healthcare and Medical Advisory Board member for Australia and New Zealand of Fresenius Medical Care. David C Wheeler has competing interests with Astellas, AstraZeneca, Boehringer Ingelheim, Eledon, GlaxoSmithKline, Galderma, Gilead, Janssen, ProKidney, Tricida, Vifor, and Zydus. Paula Woodward received financial support from The Home Network for development of training modules used during the TEACH-PD trial.
Publisher Copyright:
© 2023, Crown.
PY - 2023/12
Y1 - 2023/12
N2 - Background: Peritoneal dialysis (PD)-related infections, such as peritonitis, exit site, and tunnel infections, substantially impair the sustainability of PD. Accordingly, PD-related infection is the top-priority research outcome for patients and caregivers. While PD nurse trainers teach patients to perform their own PD, PD training curricula are not standardized or informed by an evidentiary base and may offer a potential approach to prevent PD infections. The Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes (TEACH-PD) trial evaluates whether a standardized training curriculum for PD nurse trainers and incident PD patients based on the International Society for Peritoneal Dialysis (ISPD) guidelines reduces PD-related infections compared to usual training practices. Methods: The TEACH-PD trial is a registry-based, pragmatic, open-label, multi-center, binational, cluster-randomized controlled trial. TEACH-PD will recruit adults aged 18 years or older who have not previously undergone PD training at 42 PD treatment units (clusters) in Australia and New Zealand (ANZ) between July 2019 and June 2023. Clusters will be randomized 1:1 to standardized TEACH-PD training curriculum or usual training practice. The primary trial outcome is the time to the first occurrence of any PD-related infection (exit site infection, tunnel infection, or peritonitis). The secondary trial outcomes are the individual components of the primary outcome, infection-associated catheter removal, transfer to hemodialysis (greater than 30 days and 180 days), quality of life, hospitalization, all-cause death, a composite of transfer to hemodialysis or all-cause death, and cost-effectiveness. Participants are followed for a minimum of 12 months with a targeted average follow-up period of 2 years. Participant and outcome data are collected from the ANZ Dialysis and Transplant Registry (ANZDATA) and the New Zealand Peritoneal Dialysis (NZPD) Registry. This protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines. Discussion: TEACH-PD is a registry-based, cluster-randomized pragmatic trial that aims to provide high-certainty evidence about whether an ISPD guideline-informed standardized PD training curriculum for PD nurse trainers and adult patients prevents PD-related infections. Trial registration: ClinicalTrials.gov NCT03816111. Registered on 24 January 2019.
AB - Background: Peritoneal dialysis (PD)-related infections, such as peritonitis, exit site, and tunnel infections, substantially impair the sustainability of PD. Accordingly, PD-related infection is the top-priority research outcome for patients and caregivers. While PD nurse trainers teach patients to perform their own PD, PD training curricula are not standardized or informed by an evidentiary base and may offer a potential approach to prevent PD infections. The Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes (TEACH-PD) trial evaluates whether a standardized training curriculum for PD nurse trainers and incident PD patients based on the International Society for Peritoneal Dialysis (ISPD) guidelines reduces PD-related infections compared to usual training practices. Methods: The TEACH-PD trial is a registry-based, pragmatic, open-label, multi-center, binational, cluster-randomized controlled trial. TEACH-PD will recruit adults aged 18 years or older who have not previously undergone PD training at 42 PD treatment units (clusters) in Australia and New Zealand (ANZ) between July 2019 and June 2023. Clusters will be randomized 1:1 to standardized TEACH-PD training curriculum or usual training practice. The primary trial outcome is the time to the first occurrence of any PD-related infection (exit site infection, tunnel infection, or peritonitis). The secondary trial outcomes are the individual components of the primary outcome, infection-associated catheter removal, transfer to hemodialysis (greater than 30 days and 180 days), quality of life, hospitalization, all-cause death, a composite of transfer to hemodialysis or all-cause death, and cost-effectiveness. Participants are followed for a minimum of 12 months with a targeted average follow-up period of 2 years. Participant and outcome data are collected from the ANZ Dialysis and Transplant Registry (ANZDATA) and the New Zealand Peritoneal Dialysis (NZPD) Registry. This protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines. Discussion: TEACH-PD is a registry-based, cluster-randomized pragmatic trial that aims to provide high-certainty evidence about whether an ISPD guideline-informed standardized PD training curriculum for PD nurse trainers and adult patients prevents PD-related infections. Trial registration: ClinicalTrials.gov NCT03816111. Registered on 24 January 2019.
KW - Cluster randomized controlled trial
KW - Competency assessment
KW - Cost-effectiveness
KW - Outcomes
KW - Patient education
KW - Peritoneal dialysis
KW - Peritonitis
KW - Standardized training
UR - http://www.scopus.com/inward/record.url?scp=85176440250&partnerID=8YFLogxK
U2 - 10.1186/s13063-023-07715-0
DO - 10.1186/s13063-023-07715-0
M3 - Article
C2 - 37964367
AN - SCOPUS:85176440250
SN - 1745-6215
VL - 24
JO - Trials
JF - Trials
IS - 1
M1 - 730
ER -